Taysha Gene Therapies, Inc.
TSHA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001806310
In the last 90 days, Taysha Gene Therapies, Inc. insiders filed 0 open-market purchases and 1 sale; 208 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Taysha Gene Therapies, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Of which not filed for Q2 2026 | Q2 2026 | Change |
|---|---|---|---|---|
| Holders | 191 | 2 | 208 | +19 |
| Shares | 265.6M | 82.1K | 299.6M | +34.0M (+12.8%) |
| Value | $1.18B | $366.6K | $2.03B | +$851.2M (+72.0%) |
2 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.
New holders (41)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
Sold out (22)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 2,722,165 | $12.2M |
| Point72 Asset Management, L.P. | 461,856 | $2.06M |
| Renaissance Technologies LLC | 413,203 | $1.85M |
| Superstring Capital Management LP | 258,269 | $1.15M |
| Tudor Investment Corp Et Al | 143,575 | $641.8K |
| VARCOV Co. | 58,511 | $261.5K |
| Abacus Wealth Partners, LLC | 58,241 | $260.3K |
| Legato Capital Management LLC | 21,782 | $97.4K |
| Scientech Research LLC | 21,040 | $94.0K |
| Catalyst Funds Management Pty Ltd | 15,100 | $67.5K |
| Virtu Financial LLC | 13,346 | $60.0K |
| Allegheny Financial Group LTD | 12,000 | $53.6K |
| CIBC Asset Management Inc | 11,959 | $53.5K |
| Y-Intercept (Hong Kong) Ltd | 11,486 | $51.3K |
| R Squared Ltd | 11,276 | $50.4K |
| Hudson Bay Capital Management LP | 10,740 | $48.0K |
| Quantbot Technologies LP | 524 | $2.34K |
| Sound Income Strategies, LLC | 325 | $1.40K |
| Root Financial Partners, LLC | 72 | $322 |
| MAI Capital Management | 13 | $59 |
| Assetmark, Inc | 8 | $36 |
| Ameritas Advisory Services, LLC | 1 | $4 |
Not filed for Q2 2026 yet (2)
Institutions that held Taysha Gene Therapies, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Janus Henderson Group PLC | 69,000 | $308.1K |
| CWM, LLC | 13,081 | $58.5K |